dopamine / MAO-B

Class

dopamine receptor agonist + MAO-B inhibitor (fixed-dose combination)

This mechanism combines two complementary strategies used in Parkinson's disease, a disorder marked by progressive loss of dopamine-producing neurons in the brain region that governs movement. One component is a dopamine receptor agonist, a small molecule that directly stimulates the dopamine receptors on downstream neurons, substituting for the dopamine that the brain no longer makes in sufficient quantity. The other component is a monoamine oxidase type B (MAO-B) inhibitor, which blocks the enzyme responsible for breaking down dopamine, thereby extending the duration of action of whatever dopamine remains, whether it is produced naturally or added as an agonist. Pairing the two allows each to be used at a lower dose than would be needed alone, because the MAO-B inhibitor amplifies and prolongs the agonist's effect. This combination approach broadly matters in movement disorders and other conditions where dopaminergic signaling is deficient, since it addresses both the supply side (receptor stimulation) and the clearance side (enzymatic breakdown) of the same signaling pathway, offering a way to smooth out symptom control while potentially reducing the side-effect burden associated with higher single-agent doses.